Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naïve patients and their impact on the virological failure.

Balduin M, Oette M, Däumer MP, Hoffmann D, Pfister HJ, Kaiser R.

J Clin Virol. 2009 May;45(1):34-8. doi: 10.1016/j.jcv.2009.03.002. Epub 2009 Apr 17.

PMID:
19375978
2.
3.

Genotypic resistance tests for the management of the HIV-infected patient with non-B viral isolates.

Visco-Comandini U, Balotta C.

Scand J Infect Dis Suppl. 2003;106:75-8. Review.

PMID:
15000590
4.

HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.

Ghosn J, Chaix ML, Delaugerre C.

AIDS Rev. 2009 Jul-Sep;11(3):165-73. Review.

PMID:
19654858
6.

Understanding transmitted HIV resistance through the experience in the USA.

Taiwo B.

Int J Infect Dis. 2009 Sep;13(5):552-9. doi: 10.1016/j.ijid.2008.10.008. Epub 2009 Jan 10. Review.

7.

Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure.

Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Kozal MJ, Hullsiek KH, Miller MD, Bangsberg DR, Kuritzkes DR.

AIDS. 2012 Jan 14;26(2):185-92. doi: 10.1097/QAD.0b013e32834e9d7d. Review.

8.
9.

Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase.

Ren J, Stammers DK.

Virus Res. 2008 Jun;134(1-2):157-70. doi: 10.1016/j.virusres.2007.12.018. Epub 2008 Mar 3. Review.

PMID:
18313784
10.

Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis.

Snedecor SJ, Sudharshan L, Nedrow K, Bhanegaonkar A, Simpson KN, Haider S, Chambers R, Craig C, Stephens J.

AIDS Res Hum Retroviruses. 2014 Aug;30(8):753-68. doi: 10.1089/AID.2013.0262. Epub 2014 Jul 8. Review.

11.

Impact of HIV-1 pol diversity on drug resistance and its clinical implications.

Kantor R.

Curr Opin Infect Dis. 2006 Dec;19(6):594-606. Review.

PMID:
17075337
12.

Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future.

De Clercq E.

Chem Biodivers. 2004 Jan;1(1):44-64. Review.

PMID:
17191775
13.

Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence.

Martínez-Cajas JL, Pant-Pai N, Klein MB, Wainberg MA.

AIDS Rev. 2008 Oct-Dec;10(4):212-23. Review.

PMID:
19092977
14.

Revisiting the concept of a genetic barrier to resistance.

Rusconi S.

J HIV Ther. 2006 Dec;11(4):81-3. Review. No abstract available.

PMID:
17578211
15.

DPC-083. DuPont Pharmaceuticals.

Lim ML.

Curr Opin Investig Drugs. 2001 Sep;2(9):1209-12. Review.

PMID:
11717806
16.

New developments in HIV drug resistance.

Cane PA.

J Antimicrob Chemother. 2009 Sep;64 Suppl 1:i37-40. doi: 10.1093/jac/dkp258. Review.

17.

Novel HIV-1 reverse transcriptase inhibitors.

Jochmans D.

Virus Res. 2008 Jun;134(1-2):171-85. doi: 10.1016/j.virusres.2008.01.003. Epub 2008 Mar 4. Review.

PMID:
18308412
18.
19.
20.

Microbicides for multidrug-resistant and multitropic HIV-1.

D'Cruz OJ, Uckun FM.

Curr Opin Investig Drugs. 2008 Feb;9(2):152-69. Review.

PMID:
18246518
Items per page

Supplemental Content

Write to the Help Desk